Celularity Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $26.6M-51.0% YoYTTM through 31 Dec 2025
Net Income -$91.7MTTM through 31 Dec 2025
Free Cash Flow -$13.3MTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| Gross Margin | 24.4% |
| EBITDA Margin | -198.9% |
| Operating Margin | -230.9% |
| Net Margin | -345.5% |
Returns
-242.7%ROE
-85.5%ROA
Balance Sheet Health
Debt / Equity-1.26x
Current Ratio0.16x
Net Debt$41.6M
Cash & Equivalents$6.2M
Quality Metrics
Altman Z-Score-15.19
Piotroski F-Score1 / 9
FCF Margin-49.9%
Earnings-Beat Rate0.0%
Multi-Year Trend
RevenueFY2025: $26.6M
Diluted EPS-$3.59TTMFY2025: $-3.58
Dividend
No dividend
Capital Allocation
R&D Spend$15M
Capex Intensity0.6%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Degenerative Disease | $17.3M | -64.2% | View detailsThe biomaterials commercial assets of the Degenerative Disease segment were out-licensed to NexGel, Inc. in early 2026 for up to $30 million to simplify operating structure and focus on cell therapies. |
| BioBanking | $5.4M | +5.7% | View detailsBioBanking services continue to provide stable, fee-based recurring revenue under the LifebankUSA brand. |
| Cell Therapy | $3.8M | +453.3% | View detailsCelularity is shifting its primary focus toward its core placental-derived cell therapy platform (IMPACT) and longevity applications, including cenplacel-L. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.